• Wegovy® HD available through 70,000+ US pharmacies, NovoCare® Pharmacy, select telehealth providers, and more
  • STEP UP trial data showed average weight loss of ~21% with Wegovy® HD at 72 weeks in adults with obesity if all patients stayed on treatment* and ~19% regardless of whether patients stayed on treatment**1
  • Wegovy® HD further expands the offerings for patients within the Wegovy® label, inclusive of multiple formulations, including Wegovy® pill, and indications not available with other GLP-1 weight loss medicines

PLAINSBORO, N.J., April 7, 2026 /PRNewswire/ -- Wegovy® HD (semaglutide) injection 7.2 mg is available now nationwide, delivering the highest weight loss of any Wegovy® injection to date.2 This advancement builds on the many offerings for patients within the Wegovy® label and opens up a new option for American adults living with obesity looking to lose weight and keep it off, along with diet and exercise.2